#United States #Chicago #Xentria #NYU #GL-12

Xentria Enters Exclusive Licensing Agreement with NYU

In an exciting development for cardiovascular medicine, Xentria, Inc., a biotherapeutics company at the forefront of addressing unmet medical needs, has secured an exclusive licensing deal with New York University (NYU). This strategic partnership is set to enhance the global advancement of a pioneering disease-modifying therapy specifically targeted for cardiovascular conditions.

Details of the Agreement

On December 19, 2024, Xentria announced that it would hold an exclusive worldwide license to utilize NYU's intellectual property. This collaboration aims to fuel the continued research and development of a therapeutic formulation known as GL-12. As part of this agreement, Xentria will be the clinical sponsor for any Investigational New Drug (IND) applications associated with GL-12 and is committed to commercializing this innovative therapy.

In exchange, NYU stands to benefit from annual licensing fees during the clinical phase and potential royalties on market sales once the therapy is successfully commercialized. This financial arrangement underscores both parties' dedication to transforming academic research into effective therapeutics.

A Cutting-Edge Collaboration

The partnership merges the exceptional biomedical research capabilities of NYU Langone Health with Xentria's drug development acumen. The overarching goal of this collaboration is to accelerate scientific breakthroughs, ensuring that patients gain access to effective treatments more rapidly. By combining their expertise, Xentria and NYU aim to set a new standard in the development of disease-modifying therapies for cardiovascular diseases.

Tom Shea, President of Xentria, has expressed the company's enthusiasm for this collaboration. He noted, "Our commitment to advancing this drug's development is driven by our enthusiasm for collaborating with pioneering researchers like Dr. David Park of NYU Langone Health. We seek to translate their groundbreaking discoveries from the lab to clinical practice, ultimately transforming the landscape of cardiology."

About Xentria

Founded in 2020, Xentria specializes in forging innovative collaborations across the biopharmaceutical sector, prioritizing ambitious drug development initiatives. The company's name, derived from "centrality," reflects its mission to bring together diverse perspectives to advance drug innovation through meaningful patient engagement.

Headquartered in Chicago, Xentria is dedicated to supporting the growing life sciences initiatives that cater to global audiences. The company's commitment to fostering diversity, individualism, and sustainable practices positions it as a leader in the biotherapeutics field.

For more information on Xentria and its initiatives, please visit Xentria's official website. This partnership with NYU represents a significant step forward in the fight against cardiovascular disease, with hopes of delivering innovative treatments to patients worldwide.